查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1471981

经黏膜给药系统市场规模和预测、全球和地区份额、趋势和成长机会分析报告范围：按系统、最终用户和地理位置

Transmucosal Drug Delivery Systems Market Size and Forecast, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By System, End User, and Geography
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5个工作天内

价格
简介目录

经黏膜给药系统市场价值2023年为802.1亿美元，到2031年将达到1,294.6亿美元；预计2023年至2031年复合年增长率为6.2%。

推动市场成长的关键因素是疾病管理中药物输送系统的持续采用，推动了跨黏膜药物输送系统市场的成长。此外，新药物分子和生物製剂的开发也有助于市场成长。然而，与生物相容性和有限的候选药物相关的担忧阻碍了市场的成长。

经黏膜给药系统市场的市场趋势：

将奈米技术整合到跨黏膜药物递送系统中，可以设计奈米级药物载体，从而增强药物的理化性质并靶向递送至黏膜组织。已经提出了几种将含药物奈米粒子（NP）加载到颊粘膜上以进行局部和全身应用的策略。人们对开发黏膜黏附颊配方特别是包含含有奈米粒子的黏膜黏附膜的水凝胶复合材料产生了浓厚的兴趣。例如，多学科数位出版研究所 (MDPI) 于 2020 年 8 月发表的一篇评论文章讨论了二氧化硅奈米粒子在跨黏膜药物输送中的各种应用。该文章的结论是，二氧化硅奈米颗粒已显示出作为跨黏膜药物递送的有效药物奈米载体的前景。这是因为它们可以使用简单的方法轻鬆製备，并提供对颗粒大小和形状的控制、高载药量和受控的药物输送。透过合成具有不同官能基的不同类型的二氧化硅奈米颗粒，可以实现更好的药物递送功效。

因此，药物输送系统的此类技术进步预计将在未来几年带来新的市场趋势。

经黏膜给药系统市场：细分概述

经黏膜给药系统市场根据系统和最终用户进行细分。

依系统划分，市场分为鼻肺、口腔和舌下、阴道等。鼻肺部分在 2023 年占据最大的经黏膜给药系统市场份额，预计 2023-2031 年复合年增长率最高。颊部给药途径是一种非侵入性局部方法，其中药物被保留或施用于颊腔中，即脸颊和牙龈之间的空间。药物经由口腔黏膜吸收后，经由颈静脉绕过肠道进入体循环。这种给药方式具有许多优点，例如起效快、生物利用度高于口服途径。这种方法还可以避免首过代谢，从而保护其免于在胃肠道中降解。

就最终用户而言，经黏膜给药系统市场分为医疗机构、家庭护理机构等。 2023 年，医疗保健设施领域占据最大的市场份额。家庭护理设置领域预计在 2023 年至 2031 年期间复合年增长率最高。

经黏膜给药系统市场：地理概况

经黏膜给药系统市场报告的范围涉及北美（美国、加拿大和墨西哥）、欧洲（西班牙、英国、德国、法国、义大利和欧洲其他地区）、亚太地区（韩国、中国） 、印度、日本、澳洲和亚太其他地区）、中东和非洲（南非、沙乌地阿拉伯、阿联酋以及中东和非洲其他地区）以及南美洲和中美洲（巴西、阿根廷和南美洲和中美洲其他地区）。就收入而言，2023年北美将占据最大的经黏膜给药系统市场份额。这可以归因于糖尿病、气喘和心臟病等慢性病病例的增加，以及主要参与者推出的产品数量的增加。

目录

第 1 章：简介

第 2 章：执行摘要

  • 重要见解
  • 市场吸引力分析

第 3 章：研究方法

第 4 章：经黏膜给药系统市场格局

  • 概述
  • PEST分析
  • 生态系分析
    • 价值链供应商名单

第 5 章：经黏膜给药系统市场 - 主要市场动态

  • 主要市场驱动因素
  • 主要市场限制
  • 主要市场机会
  • 未来的趋势
  • 驱动因素和限制因素的影响分析

第 6 章：经黏膜给药系统市场 - 全球市场分析

  • 经黏膜给药系统 - 全球市场概览
  • 经黏膜给药系统 - 全球市场与 2031 年预测

第 7 章：经黏膜给药系统市场 - 收入分析 - 按系统，2021-2031 年

  • 概述
  • 鼻肺
  • 颊和舌下
  • 阴道
  • 其他的

第 8 章：经黏膜给药系统市场 - 收入分析 - 按最终用户，2021-2031 年

  • 概述
  • 卫生保健设施
  • 家庭护理设置
  • 其他的

第 9 章：经黏膜给药系统市场 - 收入分析，2021-2031 - 地理分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

註 - 将为以下提到的地区/国家提供类似的分析

  • 欧洲
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 英国
    • 欧洲其他地区
  • 亚太
    • 澳洲
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地区

第 10 章：产业格局

  • 併购
  • 协议、合作、合资企业
  • 新产品发布
  • 扩张和其他策略发展

第 11 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与专注

第 12 章：经黏膜给药系统市场 - 主要公司概况

  • Teva Pharmaceutical Industries Ltd
  • Cigna Corporation
  • BioDelivery Sciences International, Inc
  • 3M
  • Henkel Finland Oy
  • GlaxoSmithKline plc
  • Aquestive Therapeutics, Inc
  • Camurus AB
  • Ximedica
  • Noven Pharmaceuticals, Inc

第 13 章：附录

简介目录
Product Code: TIPRE00004209

The transmucosal drug delivery systems market was valued at US$ 80.21 billion in 2023 to US$ 129.46 billion by 2031; it is estimated to register a CAGR of 6.2% from 2023 to 2031.

Key factors driving the market growth are the rising adoption of drug delivery systems for disease management propels the transmucosal drug delivery systems market growth. Additionally, the development of new drug molecules and biological formulations is contributing to market growth. However, the concerns associated with biocompatibility and limited drug candidates hamper the market growth.

Market Trends of the Transmucosal Drug Delivery Systems Market:

Integration of nanotechnology into transmucosal drug delivery systems enables the design of nanoscale drug carriers that can enhance the physicochemical properties of the drug and target delivery to the mucosal tissues. Several strategies have been suggested for loading drug-containing nanoparticles (NPs) onto the buccal mucosa for local and systemic applications. There has been significant interest in developing mucoadhesive buccal formulations, particularly hydrogel composites that incorporate mucoadhesive films containing NPs. For instance, a review article published by the Multidisciplinary Digital Publishing Institute (MDPI) in August 2020 discussed various applications of silica NPs in transmucosal drug delivery. The article concluded that silica nanoparticles have shown promise as effective drug nanocarriers for transmucosal drug delivery. This is because they can be easily prepared using simple methods and offer control over particle size and shape, high drug loading capacity, and controlled drug delivery. By synthesizing different types of silica NPs with various functional groups, it is possible to achieve even greater drug delivery efficacy.

Therefore, such technological advancements in the drug delivery systems are expected to bring new market trends in the coming years.

Transmucosal Drug Delivery Systems Market: Segmental Overview

The transmucosal drug delivery systems market is segmented on the basis of systems and end user.

By systems, the market is segmented into nasopulmonary, buccal & sublingual, vaginal, and others. The nasopulmonary segment held the largest transmucosal drug delivery systems market share in 2023 and is anticipated to register the highest CAGR during 2023-2031. The buccal route of drug administration is a noninvasive, topical method in which drugs are held or applied in the buccal cavity, i.e., the space between the cheek and gums. After their absorption through the oral mucosa, drugs enter the systemic circulation through the jugular vein, bypassing the intestines. This drug administration has many advantages, such as rapid onset of action and a higher bioavailability than the oral route. This method also evades first-pass metabolism, which protects it from degradation in the gastrointestinal (GI) tract.

In terms of end user, the transmucosal drug delivery systems market is segmented into healthcare facilities, homecare settings, and others. The healthcare facilities segment held the largest market share in 2023. The market growth of this segment can be attributed to the availability of better facilities and skilled physicians in hospitals. The homecare settings segment is anticipated to register the highest CAGR during 2023-2031.

Transmucosal Drug Delivery Systems Market: Geographical Overview

The scope of the transmucosal drug delivery systems market report entails North America (the US, Canada, and Mexico), Europe (Spain, the UK, Germany, France, Italy, and the Rest of Europe), Asia Pacific (South Korea, China, India, Japan, Australia, and the Rest of Asia Pacific), Middle East & Africa (South Africa, Saudi Arabia, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). In terms of revenue, North America held the largest transmucosal drug delivery systems market share in 2023. The US dominates the market in this region. This can be attributed to the increasing cases of chronic diseases such as diabetes, asthma, and cardiac diseases as well as the growing number of product launches by key players.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Transmucosal Drug Delivery Systems Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis
  • 4.3 Ecosystem Analysis
    • 4.3.1 List of Vendors in the Value Chain

5. Transmucosal Drug Delivery Systems Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Transmucosal Drug Delivery Systems Market - Global Market Analysis

  • 6.1 Transmucosal Drug Delivery Systems - Global Market Overview
  • 6.2 Transmucosal Drug Delivery Systems - Global Market and Forecast to 2031

7. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million) - By System, 2021-2031

  • 7.1 Overview
  • 7.2 Nasopulmonary
  • 7.3 Buccal and Sublingual
  • 7.4 Vaginal
  • 7.5 Others

8. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million) - By End User, 2021-2031

  • 8.1 Overview
  • 8.2 Healthcare Facilities
  • 8.3 Homecare settings
  • 8.4 Others

9. Transmucosal Drug Delivery Systems Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Transmucosal Drug Delivery Systems Market Overview
    • 9.1.2 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts to 2031
    • 9.1.3 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By System
    • 9.1.4 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By End User
    • 9.1.5 North America Transmucosal Drug Delivery Systems Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Transmucosal Drug Delivery Systems Market
        • 9.1.5.1.1 United States Transmucosal Drug Delivery Systems Market, by System
        • 9.1.5.1.2 United States Transmucosal Drug Delivery Systems Market, by End User
      • 9.1.5.2 Canada Transmucosal Drug Delivery Systems Market
        • 9.1.5.2.1 Canada Transmucosal Drug Delivery Systems Market, by System
        • 9.1.5.2.2 Canada Transmucosal Drug Delivery Systems Market, by End User
      • 9.1.5.3 Mexico Transmucosal Drug Delivery Systems Market
        • 9.1.5.3.1 Mexico Transmucosal Drug Delivery Systems Market, by System
        • 9.1.5.3.2 Mexico Transmucosal Drug Delivery Systems Market, by End User

Note - Similar analysis would be provided for below mentioned regions/countries

  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Transmucosal Drug Delivery Systems Market - Key Company Profiles

  • 12.1 Teva Pharmaceutical Industries Ltd
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments

Note - Similar information would be provided for below list of companies

  • 12.2 Cigna Corporation
  • 12.3 BioDelivery Sciences International, Inc
  • 12.4 3M
  • 12.5 Henkel Finland Oy
  • 12.6 GlaxoSmithKline plc
  • 12.7 Aquestive Therapeutics, Inc
  • 12.8 Camurus AB
  • 12.9 Ximedica
  • 12.10 Noven Pharmaceuticals, Inc

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud